Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock
Chief Scientific Officer Daniel Tardiff of Camp4 Therapeutics sold 1,738 shares of the company's common stock on August 19, 2026, for a total of $8,272. The shares were sold at $4.76 each and were purchased through the company's Employee Stock Purchase Plan from January 1, 2026, to June 30, 2026. Despite Camp4 shares delivering a 202% return over the past year, the stock is currently near its InvestingPro Fair Value estimate.
The company boasts a strong balance sheet, with more cash than debt and liquid assets exceeding short-term obligations. Investors can find additional valuation metrics and 7 ProTips on the InvestingPro platform. Recently, CAMP4 Therapeutics received attention from analysts, including JPMorgan upgrading its stock rating from Neutral to Overweight and increasing its price target to $9.00.
Chardan also initiated coverage on the company with a buy rating and a price target of $6.50, highlighting optimism about the clinical-stage biotechnology company's prospects.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
